title: MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments.
abstract: The MEK5-ERK5 pathway is a mammalian mitogen-activated protein (MAP) kinase cascade that is not well studied compared to other MAP kinase cascades. Two independent studies by Al-Ejeh et al. and Ortiz-Ruiz et al. published in Oncotarget last year concluded that ERK5 is an attractive target in triple negative breast cancer. In this perspective, we briefly describe the findings of these studies and propose the use of pharmacological inhibition of ERK5 in combination with chemotherapy against triple negative breast cancer because MEK5-ERK5 overexpression associates with poor survival of patients treated with chemotherapy.
authors: QIMR Berghofer Medical Research Institute, Herston QLD, Australia.
authors: Mariska
authors: M
authors: Miranda
authors: QIMR Berghofer Medical Research Institute, Herston QLD, Australia.
authors: Esdy
authors: E
authors: Rozali
authors: QIMR Berghofer Medical Research Institute, Herston QLD, Australia.
authors: Kum Kum
authors: KK
authors: Khanna
authors: QIMR Berghofer Medical Research Institute, Herston QLD, Australia.
authors: Fares
authors: F
authors: Al-Ejeh
keywords: ERK5/MAPK7; MEK5/MAP2K5; TNBC; chemo-resistance; triple negative breast cancer